Feature Article | Leen Kawas On Why Health Innovation Only Matters If It's Built For Access

Leen Kawas believes a therapy that cannot reach the patients who need it is not a true breakthrough. As Managing General Partner at Propel Bio Partners, she evaluates biotech through a third lens beyond novelty and market size: accessibility for underserved populations. This approach shows up in how companies design studies, build diagnostics, and deploy tools that work outside elite healthcare settings, from mail-in microbiome research to faster, lower-infrastructure testing. Kawas also argues the business case is real: inclusive development can expand markets, reduce payer and regulatory friction, and strengthen outcomes. Her standard is simple. Innovation is only meaningful when it is built to travel.

Read the Full Article Here